Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Achilles Therapeutics Ltd.. (12/7/20). "Press Release: Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications". Stevenage.

Region Region United States (USA)
Organisations Organisation Achilles Therapeutics Ltd.
  Group Achilles Therapeutics (Group)
  Organisation 2 Solebury Trout
  Group PNC Financial Services (Group)
Products Product T cell therapy
  Product 2 public relations / investor relations / marcom (services)
Persons Person Stern, Lee M. (Achilles Therapeutics 202012– VP IR + External Communications based in US before Solebury Trout)
  Person 2 Ali, Iraj (Achilles Therapeutics 202011 CEO Syncona LLP 201610 Partner)

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours today announced the appointment of Lee M. Stern as VP, IR & External Communications where he will lead investor and financial communications activities. Lee joins Achilles with over 20 years of experience in investor relations, corporate finance, and corporate communications within the biotechnology sector.

“We are delighted to welcome Lee to our growing team in this new, US-based role,” said Dr. Iraj Ali, CEO of Achilles. “Lee’s experience in the healthcare industry, strong relationships with the financial community, and understanding of the capital markets will all be assets for Achilles as we progress towards obtaining initial data from our two Phase I/IIa clinical trials – CHIRON in non-small cell lung cancer and THETIS in melanoma – expected in 2021.”

Lee joins Achilles from Solebury Trout where he was a Managing Director in its Life Sciences practice. Lee received an MBA from The Wharton School of the University of Pennsylvania and a BS in Quantitative Economics from Tufts University. He is also a CFA® charterholder.

– Ends –

Notes for Editors:

About Achilles Therapeutics

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based therapies specifically targeting those clonal neoantigens.

For further information please visit the Company’s website at:

Further information:

For Investors:

Dr. Iraj Ali – Chief Executive Officer
+44 (0) 1438 906 906

Lee M. Stern – VP, IR & External Communications
+1 (646) 807-8376

For Media:

Julia Wilson – Head of Communications
+44 (0) 7818 430877

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000

Record changed: 2020-12-23


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Achilles Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top